<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinicopathological characteristics of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> vary according to geography </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study is to determine the distribution and clinicopathological characteristics of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in Taiwan </plain></SENT>
<SENT sid="2" pm="."><plain>Archival tissue from 598 malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> during the period of 1995-2002 was retrieved </plain></SENT>
<SENT sid="3" pm="."><plain>They were reclassified according to the World Health Organization classification system </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical data, including age, gender, clinical staging, and follow-up, were scrutinized </plain></SENT>
<SENT sid="5" pm="."><plain>There were 330 males and 268 females </plain></SENT>
<SENT sid="6" pm="."><plain>The median age at <z:hpo ids='HP_0003674'>onset</z:hpo> of disease was 56 years for B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (BCL), 50 years for T/NK-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (TCL), and 26 years for Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>BCL accounted for 80.6%, TCL for 12.4%, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> for 7% </plain></SENT>
<SENT sid="8" pm="."><plain>The major subtypes of non-<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> were diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp>, marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of mucosa-associated lymphoid tissue type, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unspecified peripheral TCL, and nasal type T/NK-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Nodular sclerosing subtype was the most common in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The frequencies of TCL and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> were relatively low </plain></SENT>
<SENT sid="11" pm="."><plain>For histological subtype, <z:hpo ids='HP_0002242'>enteropathy</z:hpo>-type TCL and primary bone marrow <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> had higher frequency and poorer prognosis </plain></SENT>
<SENT sid="12" pm="."><plain>The 5-year overall survival of BCL, TCL, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> was 58.9, 34.7, and 83.5%, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>To the best of our knowledge, this is the largest series study of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in Taiwan </plain></SENT>
<SENT sid="14" pm="."><plain>Immunophenotype, histological subtype, and clinical stage play significant roles in prognosis (P &lt; 0.05) </plain></SENT>
</text></document>